Panelists from the University of Houston and Houston Methodist discussed tech transfer challenges and opportunities for academic innovators. Photo courtesy

Groundbreaking and disruptive innovations across industries are coming out of research institutions, and their commercialization process is very different from other startups.

An expert panel within Technology transfer discussed some of the unique obstacles innovators face as they go from academia into the market — like patenting, funding, the valley of death, and more.

Missed the conversation? Here are eight key moments from the panel that took place at the University of Houston's Technology Bridge on Wednesday, May 19.

This event was hosted by InnovationMap and University of Houston.

“If your technology can immediately impact some industry, I think you should license out your technology. But if you think that the reward is much higher and does not yet match something in the industry, you should go the high risk, high reward path of doing it yourself. That’s a much more challenging. It takes years of work.”

— Hadi Ghasemi, co-founder of Elemental Coatings and Cullen associate professor in the department of mechanical engineering at the University of Houston, says on how tech transfer usually happens via those two pathways. Ghasemi explains that it also depends on the academic's passion for the product and interest in becoming an entrepreneur.

“There’s a mismatch in that you can have a really clinically impactful technology but still not have money to develop it into a product.” 

— Rashim Singh, co-founder of Sanarentero and a research assistant professor of pharmaceutics at the University of Houston College of Pharmacy, says on the different priorities from within academia and within the market.

“What I’ve seen is if you know you want to patent something, tell the right people early. Make sure you have the right players involved. Our tech office already has venture, Pharma, etc. partners that can help with the patent process.”

— Ginny Torno, administrative director of innovation and IT clinical systems at Houston Methodist

“You don’t need to be fully transparent about your technology. As a company, you need to have some secret sauce."

— Ghasemi says on the patent and paper publishing process. Academics are used to publishing their research, but when it comes to business, you need to hold some things close to the chest.

“One of the most important piece the UH Tech Bridge has provided is the wet lab space to develop these technologies a little further toward commercialization. … Wet lab is very precious space in Houston specifically because there isn’t much here.”

— Singh says on how important access to lab space is to the entrepreneur.

"“You’re starting to see more and more organizations that have innovation arms. ... There are a lot of focus on trying to make Houston another innovation hub, and I think there is more support now than even a few years ago.”

— Torno says on what's changed over the past few years, mentioning TMC3 and the Ion.

“Try to serve private capital as soon as possible. The grant money comes, and those are good and will help you prove out your technology. But once you have private money, it shows people care about your product.”

— Ghasemi says as a piece of advice for potential tech transfer entrepreneurs.

“The biggest gap is to arrange for funding — federal, private, etc. — to support during the valley of death.”

— Singh says on the struggle research-based startups, especially in drug discovery, faces as they fight to prove out their product and try to stay afloat financially.

This week's innovators to know roundup includes three experts within the tech transfer space in Houston. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: It's a very special edition of the Monday innovators to know series. On Wednesday, all three of today's innovators will join me and InnovationMap for a panel discussing technology transfer — the process in general, what resources are available within their institutions, IP and grant writing, and so much more. Read more about the panelists below and click here to register for the free event.

Ginny Torno, Administrative Director, Innovation and IT Clinical Systems at Houston Methodist

Image courtesy

Ginny Torno has a long career at Houston Methodist, including work within research. Now, she's leading innovation initiatives at the deployment level within the hospital's technology center. Torno can speak to both the research and the implementation done within innovation at Houston Methodist.

Hadi Ghasemi, co-founder of Elemental Coatings and Cullen associate professor in the department of mechanical engineering at the University of Houston

Image courtesy

Hadi Ghasemi is Cullen associate professor in the department of mechanical engineering at UH. His research interests are in nanotechnology, surface physics, and heat transfer.

In 2018, Ghasemi co-founded Elemental Coatings, formerly SurfEllent, an anti-icing and anti-scaling coatings that aims to make the many problems associated with ice and scale buildup a thing of the past.

Rashim Singh, co-founder of Sanarentero and a research assistant professor of pharmaceutics at the University of Houston College of Pharmacy

Image courtesy

Co-founder of Sanarentero, Rashim Singh is developing therapies for gut-related diseases and disorders. Focused on her company, Singh can speak to the drug discovery process, grant writing, and more within the pharmaceutical space.

From a new solar energy capturing and storing device to stem cell-based pacemakers, here are three game-changing technologies coming out of UH. Getty Images

3 innovative research projects coming out of the University of Houston

research roundup

Across the University of Houston campus, professors and researchers are creating solutions for various problems in several different industries.

From information technology benefiting police officers to stem cell-based pacemakers, here are three game-changing technologies coming out of UH.

A stem cell-based biological pacemaker

Photo via of UH.edu

A University of Houston associate professor of pharmacology is contributing to research that's taking stem cells found in fat and transforming them into heart cells to act as biologic pacemaker cells.

"We are reprogramming the cardiac progenitor cell and guiding it to become a conducting cell of the heart to conduct electrical current," says Bradley McConnell in a UH news release. McConnell's work can be found in the Journal of Molecular and Cellular Cardiology.

The treatment could replace the more than 600,000 electronic pacemakers implanted annually, These devices require regular doctors visits and aren't a permanent solution.

"Batteries will die. Just look at your smartphone," says McConnell. "This biologic pacemaker is better able to adapt to the body and would not have to be maintained by a physician. It is not a foreign object. It would be able to grow with the body and become much more responsive to what the body is doing."

Suchi Raghunathan, doctoral student in the UH Department of Pharmacological and Pharmaceutical Sciences in the College of Pharmacy, is the paper's first author, and Robert J. Schwartz, Hugh Roy and Lillian Cranz Cullen Distinguished Professor of biology and biochemistry, is another one of McConnell's collaborator.

The use of information technology to protect law enforcement

Photo via of UH.edu

A tech-optimized police force is a safe police force, according to new UH research that shows that the use of information technology can cut down on the number of police officers killed or injured in the line of duty by as much as 50 percent.

"The use of IT by police increases the occupational safety of police officers in the field and reduces deaths and assaults against police officers," says C.T. Bauer College of Business Dean Paul A. Pavlou in a news release. Pavlou co-authored a paper on the research that was published in the journal Decision Support Systems.

Pavlou, along with his colleague, Min-Seok Pang of Temple University used FBI, the federal Bureau of Justice Statistics, and U.S. Census data to build a dataset, which tracked IT use and violence against law enforcement from 4,325 U.S. police departments over a six-year period, according to the release.

The study focused on crime intelligence, prediction, and investigation. The potential for IT in the police force had yet to be realized because there hadn't been much research on the subject.

A new solar energy capture and storage technology

Image via of UH.edu

New research coming out of UH has created a new and more efficient way to capture and store solar energy. Rather than using panels that store solar energy through photovoltaic technology, the new method, which is a bit of a hybrid, captures heat from the sun and stores it as thermal energy

The research, which was described in a paper in Joule, reports "a harvesting efficiency of 73% at small-scale operation and as high as 90% at large-scale operation," according to a news release.

The author of the paper, Hadi Ghasemi, is a Bill D. Cook Associate Professor of Mechanical Engineering at UH. He says the potential is greater due to the technology being able to harvest the full spectrum of sunlight. T. Randall Lee, Cullen Distinguished University Chair professor of chemistry, is also a corresponding author.

"During the day, the solar thermal energy can be harvested at temperatures as high as 120 degrees centigrade (about 248 Fahrenheit)," says Lee, who also is a principle investigator for the Texas Center for Superconductivity at UH. "At night, when there is low or no solar irradiation, the stored energy is harvested by the molecular storage material, which can convert it from a lower energy molecule to a higher energy molecule."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”